Asset profile
SHR-A2102
Antibody–drug conjugate
Evidence outlook
No featureable registry evidence
The studies registered under this drug are withdrawn, terminated, post-marketing only, or belong to other products, so none can represent its own clinical progression.
Also in development:Non-Small Cell Lung Cancer · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
120 competitors in this universe: 5 direct rivals (same mechanism and indication), 0 same-class, 115 same-indication; 82 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| SHR-A2102: this drug | Phase 3 | Antibody–drug conjugate | Nectin-4 | ||
| Enfortumab Vedotin | Phase 3 | Antibody–drug conjugate | Nectin-4 | ||
| Zelenectide Pevedotin | Phase 2 | Peptide | Nectin-4 | ||
| 225Ac-AKY-1189 | Phase 1 | Radiopharmaceutical | Nectin-4 | ||
| IPH4502 | Phase 1 | Antibody–drug conjugate | Nectin-4 | ||
| LY4052031 | Phase 1 | Antibody–drug conjugate | Nectin-4 | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR |
…and 105 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(14 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (3)
December 2026 (3)
What to watch
What to watch
What to watch
2027 (6)
March 2027 (3)
What to watch
What to watch
What to watch
April 2027 (1)
What to watch
May 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (3)
January 2028 (1)
What to watch
October 2028 (1)
What to watch
December 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.